Clinical trial
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid…
NCT00065143 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00065143 |
|---|---|
| Title | Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome |
| Official title | A Phase II Study of Clofarabine in Combination With Cytarabine (Ara-C) in Patients >/= 50 Years With Newly Diagnosed and Previously Untreated Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) (>/= 10% Bone Marrow Blasts) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | clofarabine, Ara-C |
| Enrollment | 60 |
| Start date | Jun 23, 2003 |
| Primary completion | Feb 22, 2006 |
| Completion | Feb 22, 2006 |
| First posted | Jul 18, 2003 |
| Last update posted | Nov 7, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: